Evenity (Romosozumab) Cost in Wisconsin: Pricing, Insurance, and Savings in 2026

Evenity (romosozumab-aqqg) is a sclerostin-inhibiting monoclonal antibody administered as a monthly subcutaneous injection for osteoporosis in postmenopausal women at high fracture risk. The drug carries an FDA boxed warning for cardiovascular risk. While romosozumab is prescribed for the same indication as denosumab (Prolia), teriparatide (Forteo), and abaloparatide (Tymlos), it represents a distinct therapeutic agent with a different mechanism of action.

The most important cost fact for a Wisconsin patient is not the list price, it is whether prior authorization succeeds before the first fill. Evenity is dispensed exclusively through specialty pharmacy channels, so essentially no one pays a true retail cash price for a full course, and pricing shifts year to year as manufacturer contracts and formulary placements change. The sections below separate what is stable (the FDA label, the boxed warning, the dosing schedule) from what is volatile and needs direct verification for 2026 (specific dollar amounts, specific insurer rules, specific program caps).

What does Evenity actually cost, and how confident should you be in a number?

Evenity's manufacturer list price is commonly cited in the low-to-mid $1,000s per monthly dose, with a full 12-month course (12 monthly injections of 210 mg, given as two 105 mg subcutaneous injections) running into the tens of thousands of dollars before insurance. This draft does not have a verified, dated primary source for an exact current price, and specialty biologic list prices change at least annually. Treat any specific dollar figure you see, including figures that may have appeared in earlier versions of this page, as a number that must be confirmed directly with Amgen, your specialty pharmacy, or your insurer before you rely on it for a financial decision.

What is well established, independent of price, is the mechanism by which most patients avoid paying list price at all:

1. Insurance (commercial, Medicaid, or Medicare) processes the claim first.
2. A manufacturer savings program, if you qualify, reduces or eliminates the remaining copay.
3. Patients with no insurance and low income may qualify for free drug through a manufacturer patient assistance program rather than paying any per-dose price.

Because Evenity ships through a small number of specialty pharmacy networks rather than retail chains, there is little to no meaningful price shopping between pharmacies the way there is with a generic small-molecule drug.

Does Wisconsin Medicaid cover Evenity?

Wisconsin Medicaid, including BadgerCare Plus, can cover Evenity, but coverage is not automatic. State Medicaid programs typically require prior authorization for high-cost specialty biologics tied to documented high fracture risk, which generally means evidence of a prior osteoporotic fracture, a T-score at or below a defined threshold on DXA, or documented failure or intolerance of other osteoporosis therapies such as a bisphosphonate.

Specifics that change over time and need direct confirmation before you counsel a patient or plan a treatment course:

• The exact PA criteria and required documentation for Wisconsin Medicaid fee-for-service versus each BadgerCare Plus managed care organization
• Whether a specific MCO requires a documented bisphosphonate trial before approving Evenity
• Typical PA turnaround time, which this draft cannot state precisely without a current, verifiable source

If a PA is denied, Wisconsin Medicaid enrollees generally have a right to a fair hearing appeal. A complete clinical package (DXA results, fracture history, prior therapy trials and outcomes) submitted with the initial request tends to reduce the chance of denial, though this is a general prior-authorization principle rather than a Wisconsin-specific statistic.

Does commercial insurance in Wisconsin cover Evenity?

Most major commercial insurers place specialty biologics like Evenity on a high formulary tier (often tier 4 or 5), which means higher coinsurance or copay before any savings program is applied. Large Wisconsin-market insurers commonly cover romosozumab in this way, but exact formulary tier, step-therapy sequence, and which specific bisphosphonate or antiresorptive must be tried first vary by plan and change at annual renewal. Confirm your specific plan's current formulary status, tier, and step-therapy requirement directly with your insurer rather than assuming last year's rules still apply.

A common step-therapy pattern nationally is a requirement to try or show intolerance to an oral bisphosphonate, and sometimes denosumab, before Evenity is approved. Clinical guideline bodies for osteoporosis have argued that patients at very high fracture risk can reasonably start with an anabolic agent like romosozumab rather than working through step therapy first; if your plan denies coverage on step-therapy grounds, this guideline position (verified against the current published version before citing it in an appeal) can support a formal appeal letter.

Evenity is a specialty medication everywhere in Wisconsin. Your plan directs you to a specific specialty pharmacy (commonly Optum Specialty, CVS Specialty, Accredo, or similar networks), and a claim submitted through a standard retail pharmacy will typically be rejected.

How does the Amgen/UCB savings card work?

Amgen and UCB have offered a copay savings program for commercially insured Evenity patients. Based on how manufacturer copay cards for specialty biologics generally function:

• It applies only to patients with commercial insurance that already covers Evenity; it does not work with Medicare, Medicaid, TRICARE, or other government-funded coverage.
• It typically has an annual dollar cap, which needs to be confirmed for the current program year since these caps are adjusted periodically.
• The pharmacy applies it at the point of dispensing after your insurance has processed its share, so you are not filing a separate reimbursement claim.

Because the card is capped annually and a full 12-dose course is expensive, the card may not cover every dollar of a high-coinsurance plan's cost across the entire year. Confirm the current cap and terms directly with the Amgen support program before assuming full-year coverage.

Is compounded romosozumab a real alternative?

Some compounding pharmacies advertise romosozumab, sometimes at a much lower price than the branded product. This needs a clear caution.

Romosozumab is a monoclonal antibody manufactured through a recombinant biologic process with extensive quality and purity controls. Regulatory guidance on biologic manufacturing draws a firm distinction between that kind of manufacturing and traditional pharmacy compounding of small molecules. A 503A compounding pharmacy operating under a patient-specific prescription is legal in Wisconsin as a general matter of pharmacy law, but no compounding pharmacy has demonstrated it can replicate Amgen's biologic manufacturing process. A compounded product marketed as romosozumab has not undergone the clinical trials that established Evenity's fracture-reduction benefit and cardiovascular risk profile, and osteoporosis specialty societies do not treat compounded biologics as therapeutic equivalents to the FDA-approved product. Given the boxed cardiovascular warning on the approved drug, using an unvalidated compounded version introduces a risk profile that cannot be quantified from existing evidence. This is a site-judgment caution, not a claim about any specific compounding pharmacy's product.

What if you have no insurance?

Amgen has historically operated a patient assistance program for eligible uninsured or underinsured patients, sometimes referenced as a "Safety Net" style foundation program, that can provide the drug at no cost to qualifying low-income patients. Income thresholds, the specific application process, and documentation requirements change and should be confirmed directly with the current program rather than assumed from a prior year's figures. General directories of pharmaceutical assistance resources, including NeedyMeds, can help identify current programs.

Can you get Evenity through telehealth in Wisconsin?

Wisconsin permits telehealth prescribing generally, and an evaluation for Evenity (review of DXA results, fracture history, and cardiovascular risk factors) can reasonably occur over a video visit. The injection itself is a separate physical step: it requires in-person administration by a provider or a patient trained in self-injection, since each monthly dose is two sequential subcutaneous injections. A telehealth prescribing visit plus in-person or trained at-home injection is a workable hybrid model, particularly for patients far from a specialist, but it does not eliminate the need for in-person dosing.

Cardiovascular safety and why it affects the cost conversation

The FDA boxed warning for romosozumab reflects concerns about cardiovascular events, specifically myocardial infarction and stroke (https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf). The prescribing label recommends avoiding romosozumab in patients with myocardial infarction or stroke in the prior year. This warning emerged from a comparative trial against alendronate that showed a numerically increased rate of major adverse cardiovascular events with romosozumab. Specific event rates from the trial are not included in this draft pending verification of the primary data; an editor reviewing the original trial publication should add the precise figures before finalization.

Practically, this means a Wisconsin prescriber must screen for recent cardiovascular events and uncontrolled risk factors before submitting a prior authorization. If a patient is not a cardiovascular candidate for Evenity, the entire pricing and savings-card discussion becomes moot, and the clinical conversation shifts to an alternative agent such as denosumab or teriparatide, which have different administration schedules, monitoring needs, and cost structures that are not detailed here and should be evaluated on their own.

What is established, what is plausible, and what is not established

Established: Evenity is FDA-approved for postmenopausal osteoporosis at high fracture risk, dosed as 12 monthly subcutaneous injections, and carries a boxed cardiovascular warning that restricts its use in patients with a recent MI or stroke. It is distributed through specialty pharmacy channels rather than standard retail pharmacy.

Plausible but requiring current verification: Specific list prices, specific Wisconsin insurer formulary tiers and step-therapy sequences, specific Wisconsin Medicaid PA turnaround times, and the current terms and annual cap of the Amgen/UCB savings card. These are all facts that exist and are checkable, but they are not stable enough to state as fixed 2026 figures without a dated, direct source at the time of publication.

Not established: That any compounded version of romosozumab is a clinically equivalent or safe substitute for the FDA-approved biologic. No compounding pharmacy has published evidence supporting therapeutic equivalence, and the absence of clinical trial data on any compounded version means its fracture-reduction benefit and cardiovascular risk are unknown, not merely unproven.

Verification checklist: stable facts versus facts that need a 2026 check

Use this before quoting a cost or coverage figure to a patient, in a PA letter, or in an appeal.

If a number cannot be checked against a source dated to the current year, state it as approximate and flag it for the patient or the payer conversation rather than presenting it as fixed.

A note on urgent situations

New chest pain, sudden weakness, slurred speech, or signs of a stroke or heart attack after an Evenity injection are not a coverage or cost question and warrant emergency evaluation, not a call to a specialty pharmacy or insurer.